By

Admin
In the past 20 years, we’ve been very fortunate in the development of effective myeloma therapies and have seen remarkable progress for our patients. Median survivals have improved from 2 to 3 years—at best—to 3 to 5 years with transplant for younger patients, and now we’re seeing median survivals in excess of 10 years, with...
Continue Reading
For patients with newly diagnosed multiple myeloma, the addition of daratumumab to lenalidomide and dexamethasone is associated with a reduced risk for disease progression or death, according to a study published in the May 30 issue of the New England Journal of Medicine. Thierry Facon, M.D., from the University of Lille in France, and colleagues...
Continue Reading
Highlights include: • Anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma. • MGUS risk in relatives of patients with multiple myeloma. • Costs of peripheral neuropathy in patients treated for multiple myeloma. Download here: Multiple Myeloma Research Review Issue 30
Continue Reading
Guyon Espiner reveals how lung cancer patients are buying cut-price drugs from India, as other New Zealanders fundraise, petition and apply for clinical trials to access medications Pharmac won’t fund. This is the first story in a four-part investigation into how Pharmac works and whether its model is costing lives. The second story will be...
Continue Reading
Smoldering multiple myeloma (SMM) is an asymptomatic clonal plasma cell disorder and is described as an intermediate stage between monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM). In 2003, the International Myeloma Working Group (IMWG) classified patients with SMM as those who displayed an absence of end-organ damage or the signs and symptoms of amyloidosis...
Continue Reading
Lenalidomide (Revlimid) significantly reduced the risk for smoldering multiple myeloma to progress to cancer among patients with moderate to high risk, according to findings from the phase II/III E3A06 trial to be presented at the 2019 ASCO Annual Meeting. “It is pretty clear that we need to differentiate treatment of myeloma versus prevention of smoldering to developing myeloma,” Sagar...
Continue Reading
This guide is written for people who have been diagnosed with myeloma. It will also be helpful for their families, friends and health professionals. It provides information about how to live well with myeloma by explaining how to cope with the physical symptoms and side effects and practical implications of living with the disease. Being...
Continue Reading
“More protest action is on the cards if this government isn’t prepared to give Pharmac more money “, said mother of three Joy Wilkie of Ngati Tarawhai and Ngai Te Rangi descent. She is one of many who suffer from multiple myeloma, a rare type of blood cancer, that weakens the immune system, and compromises...
Continue Reading
Multiple myeloma is a disease characterized by the proliferation of plasma cells which can lead to the abnormally high production of monoclonal immunoglobulins, detected in serum and urine. These plasma cells can enter the bone marrow and replace normal myelopoiesis. Up to 90% of patients progress to bone disease, and for this reason effective imaging...
Continue Reading
1 2 3 15

Floor 7, 90 The Terrace
Wellington Central
New Zealand